| Heng Cao,Kai Liang,Peng Liu,Yonggui Hong,Jing Wang,Yuanyuan Ji,Lujuan Xu,Weilong Wu,Shengnan Guo,Xuekun Song. Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-small cell lung cancer. Oncol Transl Med, 2020, 6: 10-15. |
| Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-small cell lung cancer |
| Received:July 23, 2019 Revised:March 11, 2020 |
| View Full Text View/Add Comment Download reader |
| KeyWord:non-small cell lung cancer (NSCLC); anlotinib; tegafur gimerac; advanced stage |
| Author Name | Affiliation | E-mail | | Heng Cao | Department of Oncology, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University of | caoheng123jun@126.com | | Kai Liang | Department of Surgical Oncology, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University | | | Peng Liu | Department of Surgical Oncology, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University | | | Yonggui Hong | Department of Oncology, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University of | hygsir168@126.com | | Jing Wang | Department of Oncology, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University of | | | Yuanyuan Ji | Department of Oncology, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University of | | | Lujuan Xu | Department of Oncology, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University of | | | Weilong Wu | Department of Oncology, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University of | | | Shengnan Guo | Department of Oncology, Anyang Tumor Hospital, The Fourth Affiliated Hospital of Henan University of | | | Xuekun Song | Henan University of Chinese Medicine, Zhengzhou 450000, China | |
|
| Hits: 7281 |
| Download times: 9235 |
| Abstract: |
| Objective Anlotinib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, has
confirmed antitumor activity in lung cancer in both in vitro and in vivo assays, and has been recommended
as third-line treatment agent in non-oncogene driven non-small cell lung cancer (NSCLC). This prospective
study aimed to investigate the efficacy and safety of anlotinib plus S-1 for third- or later-line treatment in
patients with advanced NSCLC.
Methods Patients with histologically or cytologically confirmed NSCLC, and documented disease
progression following second-line chemotherapy, and/or epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) treatment were enrolled in this study. The patients were treated anlotinib (8 mg
daily d 1–14) and S-1 (60 mg/m2 d 1–14) and the treatment was repeated every 3 weeks. Treatment was
continued until disease progression or unacceptable toxicity occurred. The objective response rate (ORR),
disease control rate (DCR), progression-free survival (PFS), and adverse events (AEs) were reviewed and
evaluated.
Results Forty-one patients were enrolled in the study between June 2018 and December 2018. The total
ORR and DCR were 26.8% and 80.5%, respectively. The median PFS was 5.2 months [95% confidence
interval (CI), 3.9 to 6.6 months]. In the univariate analysis, there was a significant difference in the median
PFS between patients with brain metastases and those without brain metastases (4.8 months vs 5.9
months, respectively; P = 0.039). The Eastern Cooperative Oncology Group (ECOG) performance status (P
= 0.002), lines of therapy (P = 0.015), and therapeutic evaluation (P = 0.014) were independent factors that
influenced PFS. The most common AEs were hypertension, proteinuria, myelosuppression, gastrointestinal
reactions, fatigue, and mucositis.
Conclusion Anlotinib plus S-1 is an effective and safe regimen for advanced NSCLC as third- or later-line
therapy. |
| Close |
|
|
|